HES-3_44, IRF8-/- ES cell
ESIBIe003-A-7
General#
Cell Line |
|
| hPSCreg Name | ESIBIe003-A-7 |
| Alternative name(s) |
HES-3_44, IRF8-/- ES cell
|
| Cell line type | Human embryonic stem cell (hESC) |
| Last update | 11th March 2021 |
| User feedback | |
Provider |
|
| Generator |
Universitätsklinikum Aachen (UKA)
Contact:
Universitätsklinikum Aachen (UKA) |
| Owner | Universitätsklinikum Aachen (UKA) |
| Distributors | |
| Derivation country | Germany |
External Databases |
|
| BioSamples | SAMEA8325230 |
| CLO | CLO_0103211 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research: allowed
Clinical: not allowed
Commercial: not allowed
|
| Subclone of | |
Donor Information#
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA104620499 |
Ethics#
Also have a look at the ethics information for the parental line
ESIBIe003-A
.
| Is there an MTA available for the cell line? | Yes |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hESC Derivation#
| Date of derivation | 2005-10-03 |
| Embryo stage | Blastula with ICM and Trophoblast |
| Supernumerary embryos from IVF treatment? |
Yes
|
| PGD Embryo? |
No |
| ZP removal technique | Enzymatic |
| Cell isolation | Immunosurgery |
| Cell seeding | Isolated ICM |
| Derived under xeno-free conditions? |
No |
| Derivation under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
| Surface coating | Gelatin | |||||||||||||||||||||
| Feeder cells |
mouse embryonic fibroblast |
|||||||||||||||||||||
| Passage method |
Enzymatically
Collagenase
|
|||||||||||||||||||||
| O2 Concentration | 5 % | |||||||||||||||||||||
| CO2 Concentration | 21 % | |||||||||||||||||||||
| Medium |
Other medium:
Base medium: Knock out DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
|||||||||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation#
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
|
Genetic Modification#
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.